- Amylyx Pharmaceuticals Announces Interim Data From Ongoing Phase 2 HELIOS Clinical Trial Demonstrating Improvements in Pancreatic Function and Glycemic Control with AMX0035 in People with Wolfram Syndrome
- Amylyx Pharmaceuticals to Host Virtual Webcast to Discuss Interim Data from Phase 2 HELIOS Study of AMX0035 in Wolfram Syndrome on April 10, 2024
- Amylyx Pharmaceuticals Announces Formal Intention to Remove RELYVRIO®/ALBRIOZA™ from the Market; Provides Updates on Access to Therapy, Pipeline, Corporate Restructuring, and Strategy
- Amylyx Pharmaceuticals Appoints Bernhardt Zeiher, MD, FCCP, FACP, to its Board of Directors
- Amylyx Pharmaceuticals Announces Topline Results From Global Phase 3 PHOENIX Trial of AMX0035 in ALS
- Amylyx Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
- Amylyx Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results
- Amylyx Pharmaceuticals to Report Fourth Quarter and Full Year 2023 Financial Results on February 22, 2024
- Amylyx Pharmaceuticals to Present Updates on its AMX0114 and RELYVRIO® Programs in ALS at the 2024 Muscular Dystrophy Association (MDA) Clinical and Scientific Conference
- Amylyx Pharmaceuticals Announces Completion of Enrollment in HELIOS, a Phase 2 Study of AMX0035 for the Treatment of Wolfram Syndrome
More ▼
Key statistics
On Monday, Amylyx Pharmaceuticals Inc (AMLX:NSQ) closed at 1.98, 7.03% above its 52-week low of 1.85, set on Apr 19, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 1.90 |
---|---|
High | 2.03 |
Low | 1.90 |
Bid | 1.98 |
Offer | 2.01 |
Previous close | 1.98 |
Average volume | 2.44m |
---|---|
Shares outstanding | 67.78m |
Free float | 56.26m |
P/E (TTM) | 2.81 |
Market cap | 134.21m USD |
EPS (TTM) | 0.7045 USD |
Data delayed at least 15 minutes, as of Apr 22 2024 21:00 BST.
More ▼